What do lung cancer patients really think about their immunotherapy?

NCT ID NCT07339254

Recruiting now Knowledge-focused Sponsor: University of Southern California Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study surveys 40 adults with non-small cell lung cancer who are already receiving immunotherapy drugs like Keytruda or Opdivo. Researchers want to know how satisfied patients are with IV infusions at the hospital versus the idea of getting shots at home. The goal is to understand patient preferences to potentially improve treatment delivery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors offer immunotherapy in ways that patients prefer, possibly improving comfort and convenience.
What could go wrong: This is a small, single-center survey with only 40 people, so results may not apply to all lung cancer patients. It does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG NON-SMALL CELL CARCINOMA

Contacts and locations

Locations

Los Angeles General Medical Center
RECRUITING

Los Angeles, California, 90033, United States
USC / Norris Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.